Pacific Biosciences Of California ROE 2012-2025 | PACB
Current and historical return on equity (ROE) values for Pacific Biosciences Of California (PACB) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Pacific Biosciences Of California ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2025-09-30 | $-0.50B | $0.04B | -289.66% |
| 2025-06-30 | $-0.53B | $0.06B | -189.40% |
| 2025-03-31 | $-0.66B | $0.09B | -170.36% |
| 2024-12-31 | $-0.31B | $0.51B | -58.99% |
| 2024-09-30 | $-0.39B | $0.45B | -68.64% |
| 2024-06-30 | $-0.40B | $0.49B | -61.37% |
| 2024-03-31 | $-0.30B | $0.65B | -43.11% |
| 2023-12-31 | $-0.31B | $0.70B | -43.87% |
| 2023-09-30 | $-0.31B | $0.76B | -46.45% |
| 2023-06-30 | $-0.32B | $0.64B | -50.55% |
| 2023-03-31 | $-0.32B | $0.69B | -49.92% |
| 2022-12-31 | $-0.31B | $0.56B | -48.02% |
| 2022-09-30 | $-0.30B | $0.63B | -42.05% |
| 2022-06-30 | $-0.20B | $0.68B | -26.76% |
| 2022-03-31 | $-0.17B | $0.74B | -26.51% |
| 2021-12-31 | $-0.18B | $0.79B | -33.16% |
| 2021-09-30 | $-0.04B | $0.84B | -8.40% |
| 2021-06-30 | $-0.08B | $0.26B | -30.71% |
| 2021-03-31 | $-0.06B | $0.28B | -30.03% |
| 2020-12-31 | $0.03B | $0.34B | 20.53% |
| 2020-09-30 | $-0.05B | $0.13B | -64.56% |
| 2020-06-30 | $-0.05B | $0.04B | -98.55% |
| 2020-03-31 | $-0.05B | $0.06B | -87.60% |
| 2019-12-31 | $-0.08B | $0.06B | -121.30% |
| 2019-09-30 | $-0.12B | $0.05B | -136.90% |
| 2019-06-30 | $-0.11B | $0.08B | -106.47% |
| 2019-03-31 | $-0.11B | $0.10B | -102.35% |
| 2018-12-31 | $-0.10B | $0.11B | -94.93% |
| 2018-09-30 | $-0.09B | $0.13B | -91.63% |
| 2018-06-30 | $-0.09B | $0.09B | -96.00% |
| 2018-03-31 | $-0.09B | $0.10B | -91.63% |
| 2017-12-31 | $-0.09B | $0.09B | -100.00% |
| 2017-09-30 | $-0.09B | $0.10B | -98.11% |
| 2017-06-30 | $-0.09B | $0.12B | -93.22% |
| 2017-03-31 | $-0.08B | $0.07B | -86.43% |
| 2016-12-31 | $-0.07B | $0.09B | -76.64% |
| 2016-09-30 | $-0.06B | $0.10B | -59.46% |
| 2016-06-30 | $-0.04B | $0.11B | -46.15% |
| 2016-03-31 | $-0.03B | $0.09B | -50.42% |
| 2015-12-31 | $-0.03B | $0.07B | -65.61% |
| 2015-09-30 | $-0.05B | $0.04B | -115.29% |
| 2015-06-30 | $-0.06B | $0.03B | -131.87% |
| 2015-03-31 | $-0.07B | $0.04B | -129.47% |
| 2014-12-31 | $-0.07B | $0.06B | -108.64% |
| 2014-09-30 | $-0.06B | $0.05B | -99.61% |
| 2014-06-30 | $-0.08B | $0.06B | -104.17% |
| 2014-03-31 | $-0.08B | $0.08B | -92.40% |
| 2013-12-31 | $-0.08B | $0.07B | -86.67% |
| 2013-09-30 | $-0.08B | $0.08B | -83.00% |
| 2013-06-30 | $-0.09B | $0.10B | -77.30% |
| 2013-03-31 | $-0.09B | $0.11B | -71.40% |
| 2012-12-31 | $-0.10B | $0.11B | -68.59% |
| 2012-09-30 | $-0.10B | $0.13B | -60.38% |
| 2012-06-30 | $-0.10B | $0.15B | -56.82% |
| 2012-03-31 | $-0.10B | $0.17B | -50.81% |
| 2011-12-31 | $-0.11B | $0.19B | -49.32% |
| 2011-09-30 | $-0.12B | $0.21B | -50.15% |
| 2011-06-30 | $-0.13B | $0.23B | -62.04% |
| 2011-03-31 | $-0.15B | $0.25B | -91.92% |
| 2010-12-31 | $-0.14B | $0.28B | -146.60% |
| 2010-06-30 | $-0.09B | $0.00B | 0.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Instruments Manufacturing | $0.713B | $0.154B |
| Pacific Biosciences of California Inc., popularly known as PacBio, develops, manufactures and markets sequencing systems, which help in studying synthesis, composition, structure and regulation of deoxyribonucleic acid, popularly known as DNA. PacBio's products are based on Single Molecule, Real-Time (SMRT) technology. SMRT generates long reads that help in assembling a whole human genome from scratch, without using an existing reference genome as a template. This process is known as de novo assembly. To observe DNA replication process smoothly, PacBio offers the SMRT Cell, Phospholinked nucleotides and The PacBio RS II System. The PacBio RS II System includes the PacBio RS II instrument, consumables and software. PacBio launched its new Sequel system based on SMRT technology. PacBio deferred the gain from the Reverse Termination Fee from Illumina until the date when the associated contingency was resolved. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Thermo Fisher Scientific (TMO) | United States | $233.627B | 27.76 |
| Intuitive Surgical (ISRG) | United States | $196.001B | 76.68 |
| IDEXX Laboratories (IDXX) | United States | $56.733B | 56.34 |
| Edwards Lifesciences (EW) | United States | $48.223B | 32.33 |
| IQVIA Holdings (IQV) | United States | $41.102B | 22.92 |
| Alcon (ALC) | Switzerland | $39.514B | 26.70 |
| Mettler-Toledo (MTD) | United States | $30.348B | 35.51 |
| DexCom (DXCM) | United States | $27.184B | 37.47 |
| STERIS (STE) | Ireland | $25.935B | 26.77 |
| Waters (WAT) | United States | $23.414B | 30.96 |
| Coloplast (CLPBY) | Denmark | $20.103B | 34.31 |
| Hologic (HOLX) | United States | $16.754B | 17.60 |
| SONOVA HOLDING (SONVY) | Switzerland | $16.523B | 0.00 |
| Globus Medical (GMED) | United States | $12.375B | 25.97 |
| Penumbra (PEN) | United States | $12.275B | 86.34 |
| Masimo (MASI) | United States | $7.435B | 23.82 |
| Sysmex ADR (SSMXY) | Japan | $6.351B | 20.18 |
| Glaukos (GKOS) | United States | $5.998B | 0.00 |
| TransMedics (TMDX) | United States | $4.851B | 57.47 |
| Teleflex (TFX) | United States | $4.554B | 7.26 |
| Veracyte (VCYT) | United States | $3.356B | 38.24 |
| LivaNova (LIVN) | United Kingdom | $3.323B | 17.95 |
| Integer Holdings (ITGR) | United States | $2.968B | 13.93 |
| Elekta AB (EKTAY) | Sweden | $2.412B | 22.57 |
| Alphatec Holdings (ATEC) | United States | $2.369B | 0.00 |
| Artivion (AORT) | United States | $2.013B | 92.39 |
| UFP Technologies (UFPT) | United States | $2.009B | 26.53 |
| Nihon Kohden (NHNKY) | Japan | $1.974B | 17.23 |
| PROCEPT BioRobotics (PRCT) | United States | $1.753B | 0.00 |
| AxoGen (AXGN) | United States | $1.421B | 0.00 |
| Tandem Diabetes Care (TNDM) | United States | $1.415B | 0.00 |
| IRadimed (IRMD) | United States | $1.292B | 61.53 |
| OPKO Health (OPK) | United States | $0.998B | 0.00 |
| Integra LifeSciences Holdings (IART) | United States | $0.976B | 5.29 |
| Pulse Biosciences (PLSE) | United States | $0.969B | 0.00 |
| SiBone (SIBN) | United States | $0.757B | 0.00 |
| Beta Bionics (BBNX) | United States | $0.748B | 0.00 |
| Tactile Systems Technology (TCMD) | United States | $0.670B | 38.96 |
| Alpha Tau Medical (DRTS) | Israel | $0.636B | 0.00 |
| ORTHOFIX MEDICAL INC (OFIX) | United States | $0.567B | 0.00 |
| NeuroPace (NPCE) | United States | $0.558B | 0.00 |
| AVANOS MEDICAL, INC (AVNS) | United States | $0.551B | 10.99 |
| Mesa Laboratories (MLAB) | United States | $0.479B | 13.22 |
| OrthoPediatrics (KIDS) | United States | $0.462B | 0.00 |
| ClearPoint Neuro (CLPT) | United States | $0.438B | 0.00 |
| AngioDynamics (ANGO) | United States | $0.422B | 0.00 |
| RxSight (RXST) | United States | $0.398B | 0.00 |
| Delcath Systems (DCTH) | United States | $0.367B | 61.06 |
| Sight Sciences (SGHT) | United States | $0.364B | 0.00 |
| Semler Scientific (SMLR) | United States | $0.327B | 2.44 |
| Spectral Diagnostics (EDTXF) | Canada | $0.310B | 0.00 |
| Nano-X Imaging (NNOX) | Israel | $0.197B | 0.00 |
| 908 Devices (MASS) | United States | $0.197B | 0.00 |
| Anteris Technologies Global (AVR) | Australia | $0.186B | 0.00 |
| Inogen (INGN) | United States | $0.176B | 0.00 |
| Treace Medical Concepts (TMCI) | United States | $0.172B | 0.00 |
| Lucid Diagnostics (LUCD) | United States | $0.171B | 0.00 |
| Rapid Micro Biosystems (RPID) | United States | $0.163B | 0.00 |
| CVRx (CVRX) | United States | $0.159B | 0.00 |
| EDAP TMS S.A (EDAP) | France | $0.153B | 0.00 |
| Zomedica (ZOMDF) | United States | $0.151B | 0.00 |
| Microbot Medical (MBOT) | United States | $0.145B | 0.00 |
| Solana (HSDT) | United States | $0.144B | 0.00 |
| LENSAR (LNSR) | United States | $0.142B | 0.00 |
| Neuronetics (STIM) | United States | $0.121B | 0.00 |
| Hyperfine (HYPR) | United States | $0.120B | 0.00 |
| Accuray (ARAY) | United States | $0.095B | 0.00 |
| Sensus Healthcare (SRTS) | United States | $0.082B | 0.00 |
| DarioHealth (DRIO) | United States | $0.080B | 0.00 |
| Atossa Genetics (ATOS) | United States | $0.078B | 0.00 |
| QT Imaging Holdings (QTIH) | United States | $0.068B | 0.00 |
| InspireMD (NSPR) | United States | $0.067B | 0.00 |
| Positron (POSC) | United States | $0.057B | 0.00 |
| Spectral AI (MDAI) | United States | $0.050B | 0.00 |
| Baird Medical Investment Holdings (BDMD) | $0.034B | 0.00 | |
| Precision Optics (POCI) | United States | $0.034B | 0.00 |
| Ekso Bionics Holdings (EKSO) | United States | $0.021B | 0.00 |
| Envoy Medical (COCH) | United States | $0.020B | 0.00 |
| Vicarious Surgical (RBOT) | United States | $0.018B | 0.00 |
| NexGel (NXGL) | United States | $0.014B | 0.00 |
| SINTX TECHNOLOGIES, INC (SINT) | United States | $0.014B | 0.00 |
| Adagio Medical Holdings (ADGM) | United States | $0.014B | 0.00 |
| Check-Cap (MBAI) | Israel | $0.012B | 0.00 |
| Tenon Medical (TNON) | United States | $0.011B | 0.00 |
| PAVmed (PAVM) | United States | $0.009B | 0.00 |
| EnVVeno Medical (NVNO) | United States | $0.007B | 0.00 |
| Nanovibronix (NAOV) | United States | $0.004B | 0.00 |
| Autonomix Medical (AMIX) | United States | $0.004B | 0.00 |
| ENDRA Life Sciences (NDRA) | United States | $0.003B | 0.00 |
| Nuwellis (NUWE) | United States | $0.003B | 0.00 |
| Venus Concept (VERO) | Canada | $0.002B | 0.00 |
| ENvue Medical (FEED) | United States | $0.002B | 0.00 |
| Bluejay Diagnostics (BJDX) | United States | $0.001B | 0.00 |
| WORK Medical Technology Group (WOK) | China | $0.000B | 0.00 |
| Spinal Elements Holdings (SPEL) | United States | $0.000B | 0.00 |
| Longview Acquisition II (LGV) | United States | $0.000B | 0.00 |
| Fresenius Medical Care AG KGaA (FMS) | Germany | $0.000B | 10.28 |
| Inspira Technologies OXY B.H.N (IINN) | Israel | $0.000B | 0.00 |